- SID Score
- 7.7/10
- Fair value
- $515.10
- Generated
- Nov 2, 2026
- Model
- claude-haiku-4-5-20251001
UnitedHealth Group (UNH) is trading at $406.97 with a market capitalization of $305 billion, positioning it as a dominant player in the healthcare sector. The stock presents a compelling investment opportunity with a fair value estimate of $515.1, suggesting 26.6% upside potential, though current analyst consensus shows a more conservative average price target of $387.8. With a P/E ratio of 17.38 and SID score of 7.7/10, UNH demonstrates solid fundamentals supported by strong recent earnings performance that has consistently exceeded expectations.
UnitedHealth Group exhibits robust earnings momentum with a track record of significant earnings beat ratios across recent quarters, including a 31.9% beat in July 2026 (EPS of $6.38 vs. estimate of $4.85) and 10.2% beat in April 2026 (EPS of $7.23 vs. estimate of $6.56). The company's P/E ratio of 17.38 appears reasonable relative to its growth trajectory, though the Value grade of D suggests the stock may not offer traditional value metrics for income-focused investors. The low dividend yield of 0.03% indicates UnitedHealth prioritizes capital allocation toward growth and shareholder buybacks rather than dividend distributions, which is typical for healthcare growth companies.
The stock is trading above both its 50-day moving average of $390.2 and 200-day moving average of $361.05, confirming an uptrend with approximately 4.3% premium to the intermediate trend line and 12.7% above the long-term trend line. The RSI(14) reading of 66.1 suggests the stock is approaching overbought conditions but has not yet entered the typically problematic 70+ territory, indicating momentum remains strong but controlled. The current price of $406.97 sits comfortably in the middle of its technical range, providing both support from moving averages and room for continued appreciation toward the $515.1 fair value estimate.
Analyst & Insider Sentiment
Insider activity provides a notably bullish signal with five separate company insiders conducting purchases on October 1, 2026, including CEO Frederick McNabb III (291 shares), director Valerie Montgomery Rice (257 shares), and other board members, demonstrating significant management confidence in current valuations. Despite the insider buying enthusiasm, analyst consensus remains cautiously optimistic with a "Buy" rating but an average price target of $387.8 that is actually below the current market price, suggesting analysts may be underestimating the company's growth potential relative to recent earnings performance. The discrepancy between insider buying and analyst conservatism creates an interesting tension that favors the insiders' forward-looking perspective based on operational knowledge.
The primary risk to UnitedHealth's valuation is healthcare sector regulatory uncertainty, including potential government price controls on prescription medications and insurance reimbursement rates that could compress margins and justify the C-grade in Profitability. The neutral news sentiment and lack of recent financial data suggests investors should monitor upcoming earnings announcements for any signs of deceleration in the company's impressive beat streak, as market expectations may have risen substantially. Additionally, the RSI approaching overbought levels indicates near-term pullback risks, and the analyst consensus price target suggests potential downside to $387.8 if sentiment shifts or earnings disappoint for the first time.
UnitedHealth Group represents a compelling growth opportunity for investors seeking exposure to healthcare with strong earnings momentum and insider confidence, supported by 26.6% upside to fair value and consistent execution in beating quarterly estimates. The combination of a Momentum grade of A, Growth grade of B, and strong insider buying provides conviction that the company is executing well operationally despite the conservative analyst price targets. For growth-oriented investors with a 12-24 month investment horizon, UNH offers an attractive risk-reward profile, though value-focused investors should await a pullback toward moving average support at $390.2 or below before initiating positions given the overbought technical setup.
